fda compounding semaglutide news september 2025 Out of Shortage, Into Controversy: The Fight Over GLP-1 Hims & Hers stock falls

Confusion arose from temporary supply shortages of brand-name Ozempic and Wegovy in 20232024, but compounded semaglutide remains consistently available through licensed 503A compounding pharmacies

The group is conducting state of the art research in the field of translational physiology and has excelled in developing experimental models and assays resulting in identification and development of drugs based on the hormones GLP-1, GLP-2 and GIP

Here is an official image and detailed information about Jascayd (nerandomilast), the recently approved drug for idiopathic pulmonary fibrosis (IPF): FDA Approval News: FDA Approves Jascayd Manufacturer Site: Jascayd by Boehringer Ingelheim #Pharmacy #DrugUpdate #IdiopathicPulmonaryFibrosis #FDAApproval #Jascayd #LungHealth #PharmaceuticalSciences #HealthcareInnovation To view or add a comment, sign in 8,968 followers

Am J Physiol Regul Integr Comp Physiol 274: R23R29, 1998 [DOI] [PubMed] [Google Scholar] 25

Brand-name FDA-approved Ozempic is available at $1,299 per month